The Significance of Diagnosis in Managing Primary Hyperoxaluria Type 1 (PH1) With Oxlumo

Oxlumo (Lumasiran) has emerged as the inaugural approved treatment for Primary Hyperoxaluria Type 1 (PH1), a rare genetic disorder with the potential for kidney damage and failure. Accounting for 80% of all cases, PH1 results from mutations in the alanine glyoxylate aminotransferase (AGXT) gene, representing the most prevalent and severe form of the disease.

Timely diagnosis and intervention are pivotal in managing PH1, underscoring the significance of early detection. Oxlumo is specifically designed for this purpose, aiming to reduce oxalate levels in urine and blood. 

Administered via subcutaneous injection, Oxlumo has demonstrated promising outcomes in diminishing urinary oxalate levels. Notably, the most common side effect is an injection site reaction, and its safety has not been studied in pregnant or breastfeeding women.

Early Diagnosis Methods and Their Importance

Untreated Primary Hyperoxaluria Type 1 (PH1) poses a severe threat of kidney failure, underscoring the necessity for early diagnosis. While interventions such as dietary adjustments, increased fluid intake, and, in some cases, organ transplantation are employed, the introduction of Oxlumo signifies a groundbreaking targeted treatment for PH1. Swift identification of PH1 is crucial to prevent renal failure, prompting early adoption of conservative measures like enhanced fluid intake and oxalate crystallization inhibitors to sustain renal function.

Recognizing and Treating PH1

Oxlumo, a prescribed medication for infants, children, and adults with PH1, has exhibited efficacy in reducing urinary oxalate levels. Operating by addressing the root cause of symptoms in PH1 patients, it effectively lowers plasma and urinary oxalate levels. Early identification of at-risk relatives facilitates timely intervention and preventive measures, emphasizing the importance of detecting the condition in its initial stages. 

For those considering buying Oxlumo online, exclusively available in the US and Europe, Sansfro Health offers a reliable solution. Committed to simplifying the importation process, Sansfro Health provides precise pricing information for a smooth and transparent experience. Sansfro facilitates the importation process with authentic pricing and comprehensive assistance.

Individuals looking to import medication must furnish a valid prescription, proof of identity, details of their healthcare professional, and current address. The Sansfro team initiates the application for an import license, ensuring access to the necessary medication upon government approval. To inquire about the price of Oxlumo in India and to grasp the importation procedure, interested individuals can reach out to the Patient Support Team at (+91) 93157 05373 or via email at help@sansfro.com. 

Reference

1. https://www.ema.europa.eu/en/news/first-treatment-rare-condition-primary-hyperoxaluria-type-1 
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf 
3. https://www.kidney.org/atoz/primary-hyperoxaluria 
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329168/